Abaloparatide 3mg we yu kin yuz

▎ Abaloparatide Strukchɔ

▎ Abaloparatide Risach

Wetin na di risach bakgrɔn fɔ abaloparatide?

כstioporosis na kכmכn mכltifaktכral sεstεmik skel dizכrd we dεn kכl lכw bon mas εn maykro akitekchכral dεtiriushכn fכ di bon tisu. dis kin mek di bon dεm we de brok bכku εn i kin izi fכ frakt, wit di hip εn spεnal frakshכn na di kכmכn kכnsekvεns dεm. I kin rili impɔk di pasɛnt dɛn kwaliti fɔ layf ɛn i kin mek di disabiliti ɛn di wan dɛn we de day bɔku. Wit di akselerat glob ɔl pipul dɛm we de ol, di insidɛns fɔ ɔstioporosis de kɔntinyu fɔ go ɔp. Dɛn se 42%-56% pan di uman dɛn ɛn 27%-29% pan di man dɛn we dɔn pas 50 ia go gɛt ɔstioporotik fraktrɔs, we go mek i bi wan impɔtant pɔblik wɛlbɔdi prɔblɛm. tradishכnal כstioporosis tritmεnt dεm, lεk bisfosfכnayt εn sεlektiv εstrojen rεsεptכr mכdulet dεm (SERM), fכs mεnten di bon dεnsiti bay we dεn de inhεbit כstioklast-mεdiet bon rεsכpshכn. Bɔt dɛn efyushɔn nɔ bɔku fɔ di wan dɛn we gɛt bɔku bɔku bon mas we dɔn ridyus ɛn we gɛt ay risk fɔ brok. Pan ɔl we paratayrɔyd ɔmon (PTH) 1-34 fragmɛnt (teriparatide) na bin di fɔs anabolic ejen we di US Food and Drug Administration (FDA) bin gri fɔ, we bin ebul fɔ mek di bon dɛnsiti go ɔp ɛn ridyus di risk fɔ brok, fɔ yuz am fɔ lɔng tɛm kin gɛt limiteshɔn dɛn we inklud fɔ mek di bon dɛn nɔ go ebul fɔ du am bak, di aypa kalsiɔm, ɛn i kin mek i gɛt ɔsteosarkoma.

Agens dis bakdrop, fכ divεlכp nכvel drog dεm we de kכmbayn pכtεnt anabolik ifekt dεm we yu de avכyd dεn drawback dεm ya na implεnt. as paratayroyd hכmon-rεlatεd pεptida (PTHrP) analכg, abaloparatide de rεtεn strכng anabolik aktiviti we i de ridyus impak pan bon rεsכpshכn εn minimiz di sεrum kalsiכm fכlt, we de mek i yusful fכ כstioporosis.

Wetin na di mεkanism dεm fכ akshכn fכ abaloparatide?

Intarakshכn wit Paratayroyd כmon Risεptor 1 (PTH1R) .

rεsεpכta sεlektiv Aktibכshכn: Abaloparatide na sεlektiv agonist fכ di paratayroyd כmon rεsεpכta 1 (PTH1R). PTH1R de εksprεs bכku bכku wan pan di sεl dεm na di tisu dεm lεk bon εn kidni, we de ple wan kכl rol fכ rεgεl di bon mεtabolism. abaloparatide spεshal wan de biεn PTH1R, we de initiet wan siriכs intasεlulyar signal path dεm fכ rεgεl di bon mεtabolism. we i de biεn, i de aktibכt adenylate cyclase, we de inkrεs intasεlulyar saykli AMP (cAMP) prodakshכn fכ mכdulet sεlyul fכnshכn εn mεtabolism ^[1,2]..

difrεns frכm כda ligεnd dεm: Paratayroyd כmon (PTH) εn paratayroyd כmon-rεlatεd protin (PTHrP) dεn tu de biεn PTH1R. pan tap we PTH, PTHrP, εn Abaloparatide כl de signal tru PTH1R, dεn dכwnstrim signal path dεm difrεn. PTH εn PTHrP de sho di sem kayn afiniti fכ di R^G (GTPγS-sεnsitiv) stet fכ PTH1R. Teriparatid (TPTD, ie, 1–34 PTH) gεt fכ tεm hכy afiniti fכ di R^0 (GTPγS-insensitive) stet pas PTHrP, we de rizulta in prolכng cAMP signal we TPTD indyuz. difrεnt frכm dat, abaloparatide, we kכmכt frכm PTHrP(1–34), dεn εnjinia fכ εnhans stεbiliti εn i de כvakom εshyu dεm lεk fכ lכs di anabolik winda εn haypa kalsemia we kכnεkt wit TPTD yus. biכs di dissociation rεt fכ di PTHrP-PTH1R kכmpleks de fast pas di wan fכ di PTH-PTH1R kכmpleks, di osteogenic ifekt dεm fכ PTHrP de kכmpan wit lεs absכpshכn εn haypa kalsemia pas TPTD. Abaloparatide de inhɛrit dis rilitiv advantej ^[1,2,3]..

Rεgulεshכn כf Bon Mεtabolism

di prכmoshכn fכ di כstiojεnεsis: Abaloparatide de mek di כstioblast aktiviti, i de inkrεs di sεntesis εn diposishכn fכ di bon matris fכ protεkt di bon fכmeshכn. כstioblast dεm de sכntez εn sekret bon matris kכmכpכnεnt dεm lεk kolagen εn osteocalcin, we de minralize sכmtεm fכ fכm nyu bon tisu. stכdi dεm sho se we dεn de trit כstioporosis afta mεnoposal, abaloparatide de inkrεs di bon minral dεnsiti (BMD) bכku bכku wan na say dεm we inklud di tכtal hip, di fεmoral nεk, εn di lכmbar spayna. bay we i de stimul di εksprεshכn fכ di כsteoblast-rεlatεd jin dεm, i de upregulate di sεntesis fכ di kכl protin dεm lεk osteocalcin εn tayp I kolagen. dis de mek di trabekul tik εn di kכtikal strכng, i de εnhans di skel trεnk εn kwaliti we i de ridyus di risk fכ frakshכn ^[1,2,3]..

inhibishכn fכ bon rεsכpshכn: pan כl we Abaloparatide fכs de akt lεk anabolik ejen, i de sho sכm inhibitory ifekt dεm bak pan bon rεsכpshכn. i de mכdulet di difrεns εn aktiviti fכ כsteoklast dεm—sεl dεm we rispansabl fכ bon rεsכpshכn we de sכlv bon minral εn כrganik matris bay we dεn de rilis asid sכbstans dεm εn proteolaytik εnzym dεm. abaloparatide kin ridyus di bon rεsכpshכn rεt bay we i de dכn di difrεns fכ di כsteoklast prεkursכr sεl dεm to machכ כstioklast dεm כ sכt di layfspan fכ machכ כstioklast dεm. di tεm we i de mכdulet signal bitwin di כstioblast dεm εn di כstioklast dεm, we de mεnten di dinamik ikwilεbri bitwin bon fכmeshכn εn rεsכpshכn. fכ egzampl, i de ridyus di כsteoklast aktibכshכn εn rεsכptiv aktvכti bay we i de dכn di כsteoblast-sεkret rεsεptכr aktibכt fכ nyuklia fכktכ κB ligεnd (RANKL). difrεnt lεk teriparatide, abaloparatide nכ de inkrεs pasmak RANKL prodakshכn, we de mek i nכ de lכs di anabolik winda we de apin we rεsכpshכn ovatak fכmeshכn insay leta stej dεm ^[1,2,3]..

Figure 1 Mכdel fכ paratayroyd כmon (PTH)/teriparatide εn PTH-rεlatεd pεptida (PTHrP/abaloparatide aktibכshכn fכ paratayroyd כmon tayp 1 rεsεpכta (PTH1R)) ^[4]..

Efεkt dεm pan di kכtilaj mεtabolism (insay כstioartraytis-Rεlatεd stכdi dεm) .

Promote Cartilage Matrix Synthesis: stכdi dεm pan כstio-arthritis (OA) dεn sho se abaloparatide de εksyεrt protεktiv ifekt pan katilej. di artikul kכndrכsayt dεm de εksprεs PTH1R, εn Abaloparatide de aktibכt dis rεsεpכta, we de mek di kכndrכsayt dεm fכ sכntez kכmכpכnεnt dεm na di kכtilaj matris. fכ egzampl, stכdi dεm sho se Abaloparatide de inkrεs lubricin (Prg4) εksprεshכn, we na imכtant εkstrasεlula matris protin insay katilej we implεnt fכ mεnten jכyn lכbrikshכn εn ridyus frikshכn. i de promuot bak fכ sεntez di tayp II kolagen, di praymar kכmכpכnt fכ di kכtilaj matris, we de εp fכ mεnten di kכtilaj strכkchכral εn fכnshכnal integriti. bay we i de inkrεs sεntesis fכ dεn kכmכpכnt dεm ya na di kכtilaj matris, Abaloparatide de εp fכ ripa εn protεkt di kכtilaj tisu dεm we dεn dכn pwεl, we de slo di prכgreshכn fכ כstio-arayt ^[5]..

inhibit di kכndrכsayt haypatrכfi εn dijεnεreshכn: Abaloparatide kin sכpres di haypatrכfik difrεns prכsεs fכ di kכndrכsayt dεm. di tεm we di כstio-arthritis de go bifo, di kכndrכsayt dεm de כnda haypatrכfik difrεns, we dεn kכl di sεl vכlyum we de inkrεs εn εlevεt εksprεshכn fכ spεsifi k haypatrכfi mak dεm lεk tayp X kolagen (Col10). dis prכsεs de mek di kכtilaj matris de dכn εn di kכtilaj de dכn. stכdi dεm sho se Abaloparatide tritmεnt de εliviet di upregulashכn fכ Col10 εksprεshכn insay kכtilaj tisu we i de ridyus di nכmba fכ big haypatrכfik lεk sεl dεm. dis sho se i kin slo di kכndrכsayt haypatrכfik difrεns, mεnten di nכmal kכndrכsayt fεnotayp, we de protεkt di kכtilaj εn delay di כstio-arthritis prכgreshכn ^[5]..

Wetin na di aplikeshɔn dɛn fɔ Abaloparatide?

Ɔstioporosis Tritmɛnt fɔ di sik

Postmenopausal Osteoporosis: Abaloparatide, we na wan sεlektiv agonist fכ di parathyroid hormone receptor 1 (PTHR1), dεn sho am fכ trit osteoporosis, patikyular fכ uman dεm we postmenopausal we de risk fכ frakt כ we nכ de rεspכnd to כda tεrapi dεm. i de inkrεs di bon minral dεnsiti bכku bכku wan εn i de ridyus di insidεns εn risk fכ nyu vεrbral εn nכn vεrbral frakshכn insay uman dεm we dεn pas mεnopos.

Male Osteoporosis: Insay Chandler H in stכdi pan man osteoporosis we yuz orchidectomized rats (ORX rats, wan man osteoporosis model), Abaloparatide tritmεnt rεsult in bכku inkrεs pan BMD we dεn mεzj bay dual-energy X-ray absorptiometry (DXA) εn peripheral quantitative computed tomography (pQCT) na sayt dεm inklud di tכtal bכdi, di lכmbar spayna, di fεmur, εn di tibia. i bin impruv trabekul fכmeshכn, bon vכlyum, εn maykro akitekchכ witout inkrεs di כsteoklast nכmba dεm. Dis sho se Abaloparatide gɛt pɔtɛnɛshɛl tritmɛnt bɛnifit fɔ man ɔstioporosis ^[6]..

Post-Traumatic Osteoarthritis (PTOA) Tritmɛnt: Fɔ fala di knee PTOA induction via medial meniscus destabilization (DMM) ɔpreshɔn insay 16 wik ol man C57BL/6 mays, dɛn gi ɛvride sabkyutan injɛkshɔn fɔ 40 μg/kg Abaloparatide (ɔ salin as kɔntrol) stat 2 wiks post-surgery fɔ 6 wiks fɔ du am. Tishu analisis bin de du na 8 wik. Rizult sho se we yu kɔmpia di grup we dɛn trit wit salin, di grup we dɛn trit wit Abaloparatide sho ridyus DMM-indyuz artikul katilɛj lɔs ɛn prɛzɛv tibial sɔfays katilɛj tisu. Immunohistochemical analysis rivεl se Abaloparatide tritmεnt mitigate di upregulation fכ tayp X kolagen (Col10) in kכtilaj, inkrεs lubricin (Prg4) εksprεshכn in nכn-kalsifayd kכtilaj εria dεm, εn rεdכks di nכmba fכ big haypatrכfik sεl dεm. we sho se Abaloparatide de slo di haypatrכfik difrεns εn i de εksyεrt wan chכndrכprotεktiv ifekt insay maws PTOA, we de gi wan nyu tεrapi stratεji fכ PTOA ^[5]..

Alveolar Bone Regeneration: di post-extraction alveolar bon resorption de rili imped di sכbsכktiv כtכdכnt tut muvmεnt (OTM) כ implant plesmεnt. Tan B sεntez bayodεgradabl, bifכnkshכnal bayoaktiv kכlsyכm fכsfεt nanoblכsכm (NF) dεm we lod wit Abaloparatide (ABL), we dεn kכl ABL@NFs. dis mεtirial de sho wan porous layεr strכkchכ, hכy dכg εnkapsulεshכn efyushכn, εn εksεlεnt bayokכmpatibiliti. ABL bin initially rilis fכ rikrut stεm sεl dεm, fכlכw bay sustayn rilis כf Ca⊃2;9 εn PO4⊃3;− fכ in situ intafεshal minralayzεshכn. dis saksesfuli rεstכr mכfכlכjik εn fכnshכnal aktv alvεol bon we nכ kכmprכmis OTM ^[7]..

Refractory Hypoparathyroidism (HPT): Chamseddin R bin ripɔt wan 39 ia ol uman we gɛt iatrogenic HPT we nɔ bin ebul fɔ ajɔst di nɔmal sɛrum kalsiɔm lɛvɛl pan ɔl we dɛn bin gi am ay doz vaytamɛn D, kalsiɔm sɔpɔtmɛnt, ɛn rikombinant PTH (rPTH) injɛkshɔn. fכlכw sabkutan administreshכn fכ abaloparatide via di Simplicity pat wit klos mכnitri εn pכsכnaliz dכsin, in sεrum kalsiכm bin stil stebul na 9 mg/dL afta 2 mכnt. bay 4 mכnt, i bin de mεnten nכmal sεrum kalsiכm witout haypokalsiכm episod dεm we i de rεdכks sכmtεm sכmtεm di כral kalsiכm εn vaytam in D supliment ^[3]..

Promoting Spinal Fusion: Insay sεvikal-tכraks rivishכn כpεrayshכn, dεn bin yuz abaloparatide fכ promuot spεnal fכshכn pan pasεnshכn dεm we gεt histri כf sεvikal instεbiliti εn mכltipכl fεil sεvikal כpεrayshכn. Parikh S ɛn ɔda pipul dɛn. ripɔt wan 66 ia ol uman pasɛnt we bigin fɔ trit 80 mcg Abaloparatide ɛvride tu wiks afta dɛn dɔn ɔpreshɔn fɔ wan kɔs we dɛn bin dɔn plan fɔ 12 wik. CT skan na di sεvikal 3 εn 6 mכnt dεn sho se di sεvikal-tכraks fכs fכs fכ hεl fayn fayn wan wit nכ sayn dεm fכ nכnunion ^[8]..

Dɔn

Abaloparatide in klinik aplikeshɔn de sɛnt pan ɔstioporosis tritmɛnt. i sho fכ uman dεm we dεn pas mεnopos wit כstioporosis we gεt hכy frakshכn risk כ we nכ de rεspכnd to כda tεrapi, we de inkrεs di bon minral dεnsiti (BMD) bכku bכku wan εn ridyus di vεrbral εn nכn vεrbral frakshכn risk. fכ man כstioporosis, animal stכdi dεm sho inkrεs BMD na mכltipכl sayt dεm εn impruv bon maykro akitekchכ, we sho se pכtεnshal tεrapi valyu. insay di post-traumatic osteoarthritis, i de ridyus di kכtilaj we de lכs εn i de inhεbit di kכndrכsayt haypatrכfi fכ protεkt di kכtilaj. insay alvεolar bon rigεnεreshכn, ABL@NFs mεtirial dεm we lod wit dis dכg de protεkt bon rigεnεreshכn, we de gi sכlushכn fכ post-כtכdכnt bon ripa. Risach de sכpכt bak fכ yus am fכ rεfraktכri haypoparatayroydism εn spεnal fכshכn prכmoshכn.

Bɔt di pɔsin we rayt di buk

Di tin dɛn we wi dɔn tɔk bɔt ɔp, na ɔl di tin dɛn we Cocer Peptides dɔn du risach, ɛdit ɛn kɔmpilayt.

Sayɛns Jɔnal Author

Bin T na risachman na di Dipatmɛnt fɔ Kwɛstyɔn, Pɛkin Yunivasiti, we spɛshal pan nanomatirial ɛn dɛn aplikeshɔn dɛn na bayɔmɛdikal injinɛri. in wok de fכkus pan di disayn εn sεntesis fכ fכnshכnal nanostrukchכ dεm fכ tכgεt dכg dεlivεri εn tisu rigεnεreshכn. Tan dɔn kɔ-ɔda bɔku buk dɛn na big sayɛns jɔnal dɛn, we dɔn kɔntribyut to advansmɛnt dɛn pan nanomedisin ɛn rijeneretiv tɛrapi. Bin T de list in di rεfrεns כf saytεshכn [7].

▎ Saytayshɔn dɛn we gɛt fɔ du wit dis

[1] Shirley M. Abaloparatide: Fɔs Globɛl Aprɔval. Drugs 2017 we dɛn kɔl; 77 (12): 1363-1368.DOI: 10.1007/s40265-017-0780-7.

[2] Sliman A, Klɛmɛnt JN., ɛn ɔda pipul dɛn. Abaloparatide: Na nyu famakolojikal opshɔn fɔ ɔstioporosis. Amɛrikan Jɔnal fɔ Wɛlbɔdi-Sistem Famasi 2019; 76: 130-135.https://api.semanticscholar.org/KɔpɔsID:59338650. Di wan dɛn we de stɔdi bɔt di Baybul.

[3] Chamseddin R, Mathew A, Alzohaili O. Abstrakt #1407986: Abaloparatide Administreshɔn Tru di Simplisiti Patch: Wan Tɛrapi Opshɔn fɔ Rifraktɔri Haypoparatayroydizm Pɔst-tayroydɛktɔmi. Ɛndokrin Prɛktis 2023; 29: S57-S58.DOI: 10.1016/j.ɛprac.2023.03.131.

[4] Thompson JC, Wanderman N, Anderson P. A., Fridman B. A., ɛn ɔda pipul dɛn. Abaloparatide ɛn di Spine: Wan Narativ Rivyu. Klinik Intɛrvɛnshɔn dɛn fɔ Ɛj 2020; 15: 1023-1033, ɛn di ɔda wan dɛn. DOI:10.2147/CIA.S227611. Di wan dɛn we de wok fɔ di kɔmni.

[5] Landgrave S, Ishii T, Maynard R, ɛn ɔda pipul dɛn. 302 Abaloparatide as wan nyu tεrapi fכ posttraumatik כstio-arayt. J ɔ rnal ɔ f Klinik ɛn Transleshɔnal Sayns 2022; 6: 53. DOI: 10.1017/cts.2022.166.

[6] Chandler H, Lanske B, Varela A, ɛn ɔda pipul dɛn. Abaloparatide, we na wan nyu osteoanabolic PTHrP analכg, de inkrεs di kכrtikכl εn trabekulכr bon mas εn akitekchכ insay orchiectomized rat dεm bay we i de inkrεs bon fכmeshכn we nכ de inkrεs di bon rεsכpshכn. Bɔn 2019; 120: 148-155.DOI: 10.1016/j.bɔn.2018.10.012.

[7] Tan B, Wu Y, Wang R, ɛn ɔda pipul dɛn. Bayodigradabl Nanoflawa wit Abaloparatide Spatiotemporal Manejmɛnt fɔ Fɔnshɔnal Alviɔlar Bɔn Rijɛnɛreshɔn. Nano Lɛta 2024. https://api.semanticscholar.org/CorpusID:267655299. Di wan dɛn we de stɔdi bɔt di Baybul.

[8] Parikh S, Lubitz SE, Sharma A. MON-365 Nכvel Yuz כf Abaloparatide fכ Augmεnt Spinal Fyushכn in Pasεnt we De כnda Sεvikothorasik Rivishכn כpεrayshכn. Jɔnal fɔ di Ɛndokrin Sɔsayti 2020; 4(Saplimɛnt_1): 365.DOI: 10.1210/jendso/bvaa046.108.

ƆL DI ATIKUL ƐN PRODƆKT INFƆMƐSHƆN WE DƐN GI NA DIS WƐBSAYT NA FƆ ƆL FƆ DI INFƆMƐSHƆN ƐN FƆ EDYUKESHƆN.  

Di prɔdak dɛn we dɛn gi na dis wɛbsayt na fɔ in vitro risach nɔmɔ. in vitro risach (Latin: *in glas*, we min insay glas) dεn de du am ausayd mכtalman bכdi. Dɛn prɔdak ya nɔto mɛrɛsin, dɛn nɔ gɛt di aprɔval frɔm di US Food and Drug Administration (FDA), ɛn dɛn nɔ fɔ yuz dɛn fɔ protɛkt, trit, ɔ mɛn ɛni mɛrɛsin, sik, ɔ sik. Di lɔ nɔ gri fɔ mek dɛn put dɛn tin ya insay mɔtalman ɔ animal bɔdi ɛni we.